A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment

Amelie Griveau,Giorgio Seano,Samuel J Shelton,Robert Kupp,Arman Jahangiri,Kirsten Obernier,Shanmugarajan Krishnan,Olle R Lindberg,Tracy J Yuen,An-Chi Tien,Jennifer K Sabo,Nancy Wang,Ivy Chen,Jonas Kloepper,Louis Larrouquere,Mitrajit Ghosh,Itay Tirosh,Emmanuelle Huillard,Arturo Alvarez-Buylla,Michael C Oldham,Anders I Persson,William A Weiss,Tracy T Batchelor,Anat Stemmer-Rachamimov,Mario L Suvà,Joanna J Phillips,Manish K Aghi,Shwetal Mehta,Rakesh K Jain,David H Rowitch

DOI: https://doi.org/10.1016/j.ccell.2018.03.020

IF: 50.3

2018-05-14

Cancer Cell

Abstract:Gliomas comprise heterogeneous malignant glial and stromal cells. While blood vessel co-option is a potential mechanism to escape anti-angiogenic therapy, the relevance of glial phenotype in this process is unclear. We show that Olig2+ oligodendrocyte precursor-like glioma cells invade by single-cell vessel co-option and preserve the blood-brain barrier (BBB). Conversely, Olig2-negative glioma cells form dense perivascular collections and promote angiogenesis and BBB breakdown, leading to innate immune cell activation. Experimentally, Olig2 promotes Wnt7b expression, a finding that correlates in human glioma profiling. Targeted Wnt7a/7b deletion or pharmacologic Wnt inhibition blocks Olig2+ glioma single-cell vessel co-option and enhances responses to temozolomide. Finally, Olig2 and Wnt7 become upregulated after anti-VEGF treatment in preclinical models and patients. Thus, glial-encoded pathways regulate distinct glioma-vascular microenvironmental interactions.